Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 2, 2012, Pages 161-173

  Nunes, Marta C ^a   Madhi, Shabir A ^a,b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

Author keywords

HIV; Immunogenicity; Pneumococcal conjugate vaccine; Pneumococcal disease; Streptococcus pneumoniae

Indexed keywords

ANTIRETROVIRUS AGENT; PLACEBO; PNEUMO NOVUM; PNEUMOCOCCUS VACCINE; PREVANER; PREVENAR13; UNCLASSIFIED DRUG; AGATOLIMOD; BACTERIAL VACCINE; PNEUMOCOCCUS POLYSACCHARIDE PROTEIN CONJUGATE VACCINE; PNU IMMUNE 23; VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY RESPONSE; CD4 LYMPHOCYTE COUNT; CD4 LYMPHOCYTE PERCENTAGE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INJECTION SITE PAIN; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RECOMMENDED DRUG DOSE; REVACCINATION; REVIEW; SINGLE DRUG DOSE; SKIN REDNESS; SKIN SWELLING; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VACCINATION; ADJUVANT THERAPY; ADULT; ANEMIA; ANTIBODY TITER; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ASTHMA; BIOASSAY; CHILD; DIARRHEA; DISEASE CLASSIFICATION; DRUG DOSAGE FORM COMPARISON; DRUG ERUPTION; DRUG FEVER; ENCEPHALITIS; GEOMETRIC MEAN ANTIBODY CONCENTRATION; IMMUNOLOGICAL PARAMETERS; INJECTION SITE REACTION; OPSONOPHAGOCYTIC ACTIVITY ASSAY; PNEUMOCOCCAL INFECTION; RISK REDUCTION; SYSTEMATIC REVIEW; SYSTEMIC DISEASE; VIRUS LOAD; AIDS RELATED COMPLEX; IMMUNOLOGY; INFANT; PATHOGENICITY;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CD4 LYMPHOCYTE COUNT; CHILD; HIV; HIV INFECTIONS; HUMANS; INFANT; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 84861796251     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.8.2.18432     Document Type: Review

References (88)

1. UNICEF. Percentage of under fives with suspected pneumonia taken to appropriate health provider. http://www.childinfo.org/pneumonia-countrydatacare. php accessed July, 2011.
2. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374:893-902; PMID:19748398; http://dx.doi.org/10.1016/S0140-6736(09)61204-6
3. Nunes MC, von Gottberg A, de Gouveia L, et al. The impact of antiretroviral treatment on the burden of invasive pneumococcal disease in South African children: a time series analysis. AIDS 2011; 25:453-62; PMID:21178754; http://dx.doi.org/10.1097/QAD.0b013e328341b7f1
4. Madhi SA, Petersen K, Madhi A, Wasas A, Klugman KP. Impact of human immunodeficiency virus type 1 on the disease spectrum of Streptococcus pneumoniae in South African children. Pediatr Infect Dis J 2000; 19:1141-7; PMID:11144373; http://dx.doi.org/10.1097/00006454-200012000-00004
5. Madhi SA, Madhi A, Petersen K, Khoosal M, Klugman KP. Impact of human immunodeficiency virus type 1 infection on the epidemiology and outcome of bacterial meningitis in South African children. Int J Infect Dis 2001; 5:119-25; PMID:11724667; http://dx.doi.org/10.1016/S1201-9712(01)90085-2
6. Schuchat A, Broome CV, Hightower A, Costa SJ, Parkin W. Use of surveillance for invasive pneumococcal disease to estimate the size of the immunosuppressed HIV-infected population. JAMA 1991; 265:3275-9; PMID:2046109; http://dx.doi.org/10.1001/jama.1991.03460240071030
7. Nuorti JP, Butler JC, Gelling L, Kool JL, Reingold AL, Vugia DJ. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann Intern Med 2000; 132:182-90; PMID: 10651598
8. Jordano Q, Falco V, Almirante B, et al. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis 2004; 38:1623-8; PMID: 15156452; http://dx.doi.org/10.1086/420933
9. Jones N, Huebner R, Khoosal M, Crewe-Brown H, Klugman K. The impact of HIV on Streptococcus pneumoniae bacteraemia in a South African population. AIDS 1998; 12:2177-84; PMID:9833859; http://dx.doi.org/10.1097/00002030-199816000- 00013
10. Heffernan RT, Barrett NL, Gallagher KM, et al. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. J Infect Dis 2005; 191:2038-45; PMID:15897989; http://dx.doi.org/10.1086/430356
11. McEllistrem MC, Mendelsohn AB, Pass MA, et al. Recurrent invasive pneumococcal disease in individuals with human immunodeficiency virus infection. J Infect Dis 2002; 185:1364-8; PMID:12001059; http://dx.doi.org/10.1086/339882
12. Gilks CF, Ojoo SA, Ojoo JC, et al. Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya. Lancet 1996; 347:718-23; PMID:8602001; http://dx.doi.org/10.1016/S0140-6736(96) 90076-8
13. Mond JJ, Lees A, Snapper CM. T cell-independent antigens type 2. Annu Rev Immunol 1995; 13:655-92; PMID:7612238; http://dx.doi.org/10.1146/annurev.iy.13. 040195.003255
14. Lane HC, Masur H, Edgar LC, Whalen G, Rook AH, Fauci AS. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med 1983; 309:453-8; PMID:6224088; http://dx.doi.org/10.1056/NEJM198308253090803
15. Scriba TJ, Zhang HT, Brown HL, et al. HIV-1-specific CD4+ T lymphocyte turnover and activation increase upon viral rebound. J Clin Invest 2005; 115:443-50; PMID:15668739
16. Madhi SA, Kuwanda L, Cutland C, Holm A, Kayhty H, Klugman KP. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J 2005; 24:410-6; PMID:15876939; http://dx.doi.org/10.1097/ 01.inf.0000160942.84169.14
17. De Milito A, Morch C, Sonnerborg A, Chiodi F. Loss of memory (CD27) B lymphocytes in HIV-1 infection. AIDS 2001; 15:957-64; PMID:11399977; http://dx.doi.org/10.1097/00002030-200105250-00003
18. Eley B. Immunization in patients with HIV infection: are practical recommendations possible? Drugs 2008; 68:1473-81; PMID:18627205; http://dx.doi.org/10.2165/00003495-200868110-00001
19. Recommended adult immunization schedule-United States, 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1-4; PMID:21381442
20. Musher DM, Rueda-Jaimes AM, Graviss EA, Rodriguez-Barradas MC. Effect of pneumococcal vaccination: a comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneumonia. Clin Infect Dis 2006; 43:1004-8; PMID:16983612; http://dx.doi.org/10.1086/507699
21. Johnstone J, Marrie TJ, Eurich DT, Majumdar SR. Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia. Arch Intern Med 2007; 167:1938-43; PMID:17923592; http://dx.doi.org/10.1001/archinte. 167.18.1938
22. Vila-Corcoles A, Salsench E, Rodriguez-Blanco T, et al. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study. Vaccine 2009; 27:1504-10; PMID:19171174; http://dx.doi.org/10.1016/j.vaccine.2009.01.013
23. Musher DM, Groover JE, Rowland JM, et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination. Clin Infect Dis 1993; 17:66-73; PMID:8353248; http://dx.doi.org/10.1093/clinids/17.1.66
24. Nielsen H, Kvinesdal B, Benfield TL, Lundgren JD, Konradsen HB. Rapid loss of specific antibodies after pneumococcal vaccination in patients with human immunodeficiency virus-1 infection. Scand J Infect Dis 1998; 30:597-601; PMID:10225389; http://dx.doi.org/10.1080/00365549850161160
25. Musher DM, Manof SB, Liss C, et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis 2010; 201:516-24; PMID:20092407; http://dx.doi.org/10.1086/ 649839
26. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR Recomm Rep 2000; 49:1-35; PMID:11055835
27. O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis 2007; 7:597-606; PMID:17714673; http://dx.doi.org/10.1016/S1473- 3099(07)70210-4
28. Sloyer JL, Jr., Ploussard JH, Karr LJ, Schiffman GD. Immunologic response to pneumococcal polysaccharide vaccine in infants. Ann Otol Rhinol Laryngol Suppl 1980; 89:351-6; PMID:6778345
29. Douglas RM, Miles HB. Vaccination against Streptococcus pneumoniae in childhood: lack of demonstrable benefit in young Australian children. J Infect Dis 1984; 149:861-9; PMID:6376653; http://dx.doi.org/10.1093/infdis/149.6.861
30. Vernacchio L, Neufeld EJ, MacDonald K, et al. Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease. J Pediatr 1998; 133:275-8; PMID:9709721; http://dx.doi.org/10.1016/S0022-3476(98)70235-5
31. Chan CY, Molrine DC, George S, et al. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease. J Infect Dis 1996; 173:256-8; PMID: 8537671; http://dx.doi.org/10.1093/infdis/173.1.256
32. Storek J, Mendelman PM, Witherspoon RP, McGregor BA, Storb R. IgG response to pneumococcal polysaccharide-protein conjugate appears similar to IgG response to polysaccharide in bone marrow transplant recipients and healthy adults. Clin Infect Dis 1997; 25:1253-5; PMID:9402399; http://dx.doi.org/10. 1086/516965
33. Abraham-Van Parijs B. Review of pneumococcal conjugate vaccine in adults: implications on clinical development. Vaccine 2004; 22:1362-71; PMID:15063558; http://dx.doi.org/10.1016/j.vaccine.2004.01.029
34. Musher DM, Sampath R, Rodriguez-Barradas MC. The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence? Clin Infect Dis 2011; 52:633-40; PMID:21292668; http://dx.doi.org/10. 1093/cid/ciq207
35. Bliss SJ, O'Brien KL, Janoff EN, et al. The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease. Lancet Infect Dis 2008; 8:67-80; PMID:17974480; http://dx.doi.org/10.1016/S1473- 3099(07)70242-6
36. Feavers I, Knezevic I, Powell M, Griffiths E. Challenges in the evaluation and licensing of new pneumococcal vaccines, 7-8 July 2008, Ottawa, Canada. Vaccine 2009; 27:3681-8; PMID:19442421; http://dx.doi.org/10.1016/j. vaccine.2009.03.087
37. Siber GR, Chang I, Baker S, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 2007; 25:3816-26; PMID:17368878; http://dx.doi.org/10.1016/j.vaccine.2007.01.119
38. Madhi SA, Adrian P, Kuwanda L, et al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine 2007; 25:2451-7; PMID:17023095; http://dx.doi.org/10.1016/j. vaccine.2006.09.019
39. Madhi SA, Adrian P, Cotton MF, et al. Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. J Infect Dis 2010; 202:355-61; PMID:20583920; http://dx.doi.org/10.1086/653704
40. Jódar L, Butler J, Carlone G, et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 2003; 21:3265-72; PMID:12804857; http://dx.doi.org/10. 1016/S0264-410X(03)00230-5
41. Fernsten P, Mason KW, Yu X, et al. 13-valent pneumococcal conjugate vaccine immune sera protects against pneumococcal serotype 1, 3 and 5 bacteremia in a neonatal rat challenge model. Hum Vaccin 2011; 7:75-84; PMID:21266856; http://dx.doi.org/10.4161/hv.7.0.14566
42. Abzug MJ, Pelton SI, Song LY, et al. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 2006; 25:920-9; PMID:17006288; http://dx.doi.org/10.1097/01.inf.0000237830.33228.c3
43. King JC, Jr., Vink PE, Chang I, et al. Antibody titers eight months after three doses of a five-valent pneumococcal conjugate vaccine in HIV and non-HIV-infected children less than two years of age. Vaccine 1998; 16:361-5; PMID:9607056; http://dx.doi.org/10.1016/S0264-410X(97)80914-0
44. King JC, Jr., Vink PE, Farley JJ, et al. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children. Pediatr Infect Dis J 1996; 15:192-6; PMID:8852905; http://dx.doi.org/10.1097/00006454-199603000-00003
45. King JC, Jr., Vink PE, Farley JJ, Smilie M, Parks M, Lichenstein R. Safety and immunogenicity of three doses of a five-valent pneumococcal conjugate vaccine in children younger than two years with and without human immunodeficiency virus infection. Pediatrics 1997; 99:575-80; PMID:9093301; http://dx.doi.org/10.1542/peds.99.4.575
46. Madhi SA, Klugman KP, Kuwanda L, Cutland C, Kayhty H, Adrian P. Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination. J Infect Dis 2009; 199:1168-76; PMID:19265481; http://dx.doi.org/ 10.1086/597388
47. Nachman S, Kim S, King J, et al. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection. Pediatrics 2003; 112:66-73; PMID: 12837869; http://dx.doi.org/10.1542/peds.112.1.66
48. Spoulou VI, Tsoumas DL, Papaevangelou VG, Mostrou GI, Theodoridou MC. Immunogenicity and immunological memory induced by a 7-valent pneumococcal CRM197 conjugate vaccine in symptomatic HIV-1 infected children. Vaccine 2005; 23:5289-93; PMID:16054732; http://dx.doi.org/10.1016/j.vaccine.2005.06.002
49. Tarragó D, Casal J, Ruiz-Contreras J, et al. Assessment of antibody response elicited by a 7-valent pneumococcal conjugate vaccine in pediatric human immunodeficiency virus infection. Clin Diagn Lab Immunol 2005; 12:165-70; PMID:15643002
50. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003; 349:1341-8; PMID: 14523142; http://dx.doi.org/10.1056/NEJMoa035060
51. doh.gov.za. http://wwwdohgovza/docs/factsheets/ guidelines/ artguidelines04/intropdf.
52. Madhi SA, Cumin E, Klugman KP. Defining the potential impact of conjugate bacterial polysaccharideprotein vaccines in reducing the burden of pneumonia in human immunodeficiency virus type 1-infected and -uninfected children. Pediatr Infect Dis J 2002; 21: 393-9; PMID:12150175; http://dx.doi.org/10.1097/00006454- 200205000-00009
53. Madhi SA, Kuwanda L, Cutland C, Klugman KP. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIVinfected and -uninfected children. Clin Infect Dis 2005; 40:1511-8; PMID:15844075; http://dx.doi.org/10.1086/429828
54. Moore DP, Klugman KP, Madhi SA. Role of Streptococcus pneumoniae in hospitalization for acute community-acquired pneumonia associated with cultureconfirmed Mycobacterium tuberculosis in children: a pneumococcal conjugate vaccine probe study. Pediatr Infect Dis J 2010; 29:1099-04; PMID:21155174; http://dx.doi.org/10.1097/INF.0b013e3181eaefff
55. Madhi SA, Klugman KP. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med 2004; 10:811-3; PMID:15247911; http://dx.doi.org/10.1038/nm1077
56. Kovacs JA, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 2000; 342: 1416-29; PMID:10805828; http://dx.doi.org/10.1056/NEJM200005113421907
57. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1-207; PMID:19357635
58. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). MMWR Recomm Rep 1999; 48:1-59, 61-6; PMID:10499670
59. Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Antibodies against pneumococcal polysaccharides after vaccination in HIV-infected individuals: 5-year follow-up of antibody concentrations. Vaccine 1999; 18:524-30; PMID:10519943; http://dx.doi.org/10.1016/S0264-410X(99)00240-6
60. French N, Nakiyingi J, Carpenter LM, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000; 355:2106-11; PMID: 10902624; http://dx.doi.org/10.1016/S0140-6736(00) 02377-1
61. López-Palomo C, Martin-Zamorano M, Benitez E, et al. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination. J Med Virol 2004; 72:517-24; PMID: 14981752; http://dx.doi.org/10.1002/jmv.20045
62. Rodriguez-Barradas MC, Alexandraki I, Nazir T, et al. Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine. Clin Infect Dis 2003; 37:438-47; PMID:12884170; http://dx.doi.org/10.1086/375841
63. Hung CC, Chen MY, Hsieh SM, Hsiao CF, Sheng WH, Chang SC. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study. Vaccine 2004; 22:2006-12; PMID:15121313; http://dx.doi.org/10.1016/j.vaccine.2003.10.030
64. Watera C, Nakiyingi J, Miiro G, et al. 23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort. AIDS 2004; 18:1210-3; PMID:15166540; http://dx.doi.org/ 10.1097/00002030-200405210-00018
65. Pedersen RH, Lohse N, Ostergaard L, Sogaard O. The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review. HIV Med 2011; 12:323-33; PMID:21059168; http://dx.doi.org/10.1111/j. 1468-1293.2010.00892.x
66. Grau I, Pallares R, Tubau F, et al. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med 2005; 165:1533-40; PMID:16009870; http://dx.doi.org/10.1001/archinte.165.13.1533
67. Dworkin MS, Ward JW, Hanson DL, Jones JL, Kaplan JE. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis 2001; 32:794-800; PMID:11229848; http://dx.doi.org/10.1086/319218
68. Teshale EH, Hanson D, Flannery B, et al. Effectiveness of 23-valent polysaccharide pneumococcal vaccine on pneumonia in HIV-infected adults in the United States, 1998-2003. Vaccine 2008; 26:5830-4; PMID:18786586; http://dx.doi.org/10.1016/j.vaccine.2008.08.032
69. Ahmed F, Steinhoff MC, Rodriguez-Barradas MC, Hamilton RG, Musher DM, Nelson KE. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial. J Infect Dis 1996; 173:83-90; PMID:8537687; http://dx.doi.org/10.1093/infdis/173.1.83
70. Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIVinfected adults. Vaccine 2000; 19:886-94; PMID: 11115712; http://dx.doi.org/10.1016/S0264-410X(00)00232-2
71. Feikin DR, Elie CM, Goetz MB, et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine 2001; 20:545-53; PMID:11672921; http://dx.doi.org/10.1016/S0264-410X(01)00347-4
72. Miiro G, Kayhty H, Watera C, et al. Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine. J Infect Dis 2005; 192:1801-5; PMID:16235180; http://dx.doi.org/10.1086/497144
73. Lesprit P, Pedrono G, Molina JM, et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 2007; 21:2425-34; PMID:18025879; http://dx.doi.org/10.1097/QAD.0b013e3282887e91
74. Gordon SB, Kayhty H, Molyneux ME, et al. Pneumococcal conjugate vaccine is immunogenic in lung fluid of HIV-infected and immunocompetent adults. J Allergy Clin Immunol 2007; 120:208-10; PMID: 17544493; http://dx.doi.org/10. 1016/j.jaci.2007.03.050
75. Chen M, Ssali F, Mulungi M, et al. Induction of opsonophagocytic killing activity with pneumococcal conjugate vaccine in human immunodeficiency virusinfected Ugandan adults. Vaccine 2008; 26:4962-8; PMID:18639599; http://dx.doi.org/10.1016/j.vaccine.2008.06.093
76. Peñaranda M, Payeras A, Cambra A, Mila J, Riera M. Conjugate and polysaccharide pneumococcal vaccines do not improve initial response of the polysaccharide vaccine in HIV-infected adults. AIDS 2010; 24:1226-8; PMID:20299956; http://dx.doi.org/10.1097/QAD.0b013e3283389de5
77. Crum-Cianflone NF, Huppler Hullsiek K, Roediger M, et al. A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults. J Infect Dis 2010; 202:1114-25; PMID:20795819; http://dx.doi.org/10.1086/656147
78. Søgaard OS, Schonheyder HC, Bukh AR, et al. Pneumococcal conjugate vaccination in persons with HIV: the effect of highly active antiretroviral therapy. AIDS 2010; 24:1315-22; PMID:20559037; http://dx.doi.org/10.1097/QAD. 0b013e328339fe0b
79. Søgaard OS, Lohse N, Harboe ZB, et al. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial. Clin Infect Dis 2010; 51:42-50; PMID:20504165; http://dx.doi.org/10.1086/653112
80. French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362:812-22; PMID: 20200385; http://dx.doi.org/10.1056/NEJMoa0903029
81. Concepcion NF, Frasch CE. Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001; 8:266-72; PMID:11238206
82. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348:1737-46; PMID:12724479; http://dx.doi.org/10.1056/ NEJMoa022823
83. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32-41; PMID:19947881; http://dx.doi.org/10.1086/648593
84. Klugman KP. Efficacy of pneumococcal conjugate vaccines and their effect on carriage and antimicrobial resistance. Lancet Infect Dis 2001; 1:85-91; PMID: 11871480; http://dx.doi.org/10.1016/S1473-3099(01)00063-9
85. Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005; 294:2043-51; PMID: 16249418; http://dx.doi.org/10. 1001/jama.294.16.2043
86. Cohen AL, Harrison LH, Farley MM, et al. Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization. AIDS 2010; 24:2253-62; PMID:20671543; http://dx.doi.org/10.1097/QAD.0b013e32833d46fd
87. Albrich WC, Baughman W, Schmotzer B, Farley MM. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine. Clin Infect Dis 2007; 44:1569-76; PMID:17516400; http://dx.doi.org/10.1086/518149
88. Albrich WC, Madhi SA, Lafond KE, Klugman KP. Herd immunity after pneumococcal conjugate vaccination. Lancet 2007; 370:218-9, author reply 9-20; PMID:17658389; http://dx.doi.org/10.1016/S0140-6736(07)61119-2